BC can be multifocal and exhibits pronounced intra- and intertumoral antigen heterogeneity, including variability in EGFR, Nectin-4 and TROP-2 expression, driven by genetic mutations, altered molecular pathways, and influences of the tumor microenvironment [22,40,41]. Here, TACSTD2 is linked to breast cancer.